Literature DB >> 33215959

Drug Discovery Targeting COVID-19.

Timothy P Spicer1.   

Abstract

Entities:  

Year:  2020        PMID： 33215959      PMCID： PMC8960151          DOI： 10.1177/2472555220970966

Source DB:  PubMed          Journal:  SLAS Discov        ISSN： 2472-5552            Impact factor:   3.341


× No keyword cloud information.
  7 in total

Review 1.  RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.

Authors:  Wei Zhu; Catherine Z Chen; Kirill Gorshkov; Miao Xu; Donald C Lo; Wei Zheng
Journal:  SLAS Discov       Date:  2020-07-13       Impact factor: 3.341

Review 2.  A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.

Authors:  Dawid Maciorowski; Samir Z El Idrissi; Yash Gupta; Brian J Medernach; Michael B Burns; Daniel P Becker; Ravi Durvasula; Prakasha Kempaiah
Journal:  SLAS Discov       Date:  2020-09-17       Impact factor: 3.341

3.  Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.

Authors:  Mariafrancesca Scalise; Cesare Indiveri
Journal:  SLAS Discov       Date:  2020-06-05       Impact factor: 3.341

4.  Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3.

Authors:  Rajdeep S Virdi; Robert V Bavisotto; Nicholas C Hopper; Nemanja Vuksanovic; Trevor R Melkonian; Nicholas R Silvaggi; David N Frick
Journal:  SLAS Discov       Date:  2020-09-28       Impact factor: 3.341

5.  High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2.

Authors:  Emery Smith; Meredith E Davis-Gardner; Ruben D Garcia-Ordonez; Tu-Trinh Nguyen; Mitchell Hull; Emily Chen; Pierre Baillargeon; Louis Scampavia; Timothy Strutzenberg; Patrick R Griffin; Michael Farzan; Timothy P Spicer
Journal:  SLAS Discov       Date:  2020-10-10       Impact factor: 3.341

Review 6.  Based on Principles and Insights of COVID-19 Epidemiology, Genome Sequencing, and Pathogenesis: Retrospective Analysis of Sinigrin and ProlixinRX (Fluphenazine) Provides Off-Label Drug Candidates.

Authors:  Jilan Nazeam; Esraa Z Mohammed; Mariam Raafat; Mariam Houssein; Asmaa Elkafoury; Dina Hamdy; Lina Jamil
Journal:  SLAS Discov       Date:  2020-08-17       Impact factor: 3.341

7.  Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.

Authors:  Abid H Banday; Shameem A Shameem; Sheikh J Ajaz
Journal:  SLAS Discov       Date:  2020-07-21       Impact factor: 3.341
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.